1. Home
  2. MFA vs KALV Comparison

MFA vs KALV Comparison

Compare MFA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$9.53

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.80

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
KALV
Founded
1997
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MFA
KALV
Price
$9.53
$26.80
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$11.05
$32.60
AVG Volume (30 Days)
1.4M
5.2M
Earning Date
05-05-2026
07-09-2026
Dividend Yield
14.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
N/A
$185.42
Revenue Next Year
$10.02
$59.23
P/E Ratio
$7.75
N/A
Revenue Growth
N/A
495.66
52 Week Low
$8.78
$9.83
52 Week High
$10.57
$26.85

Technical Indicators

Market Signals
Indicator
MFA
KALV
Relative Strength Index (RSI) 43.43 75.12
Support Level $9.38 $14.25
Resistance Level $9.79 $26.85
Average True Range (ATR) 0.21 0.07
MACD -0.05 -0.16
Stochastic Oscillator 19.20 77.27

Price Performance

Historical Comparison
MFA
KALV

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: